Dr. Ling Wu is a cancer immunologist and advisor for the International Society of Pharmaceutical Engineering (ISPE). He is currently the co-founder of ChemT Biotechnology, which is advancing cell and gene therapy (CGT) with artificial intelligence technology. With over a decade of expertise in cell and gene therapy (CGT) research and development, Dr. Wu previously led the CGT group at BeiGene, driving advancements in therapeutic innovation. He was the recipient of the Outstanding Research Fellow Award, and earned a PhD from the National University of Singapore, where he focused on groundbreaking CGT methodologies.
2025
Industrial - Presentation